Adam Ogden's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
2010 2020 0 25 50 75 100 125 150 175 200 225 250 Published Papers A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore Pentostatin in steroid-refractory acute graft-versus-host disease. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430 In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy. Photosensitive epilepsy A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia. Suramin as a Chemosensitizer: Oral Pharmacokinetics in Rats Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5‐Subtype Selective GABAA‐Positive Allosteric Modulator PF‐06372865 in Healthy Volunteers J06 A randomized, double-blind, placebo-controlled phase ii efficacy and safety study of the PDE10A inhibitor PF-02545920 in huntington disease (amaryllis) Translational receptor occupancy for the 5-HT4 partial agonist PF-04995274 in rats, non-human primates and healthy volunteers Evaluation of Pharmacokinetic/Pharmacodynamic Relationships of PD-0162819, a Biotin Carboxylase Inhibitor Representing a New Class of Antibacterial Compounds, Using In Vitro Infection Models Chemosensitization of pancreatic tumors with the use of low-dose suramin (2) First-inHuman Assessment of the Novel PDE 2 A PET Radiotracer 18 FPF-05270430 (2) First-inHuman Studies of Brain PDE 2 A First in Human Assessment of the Novel PDE 2 A PET Radiotracer 18 FPF-05270430 (0) Pharmacokinetic/pharmacodynamic evaluation of acetylcholine modulation by donepezil in rats and projection to human Quantitative Systems Pharmacology (QSP 1–9) Attended 1:00 pm – 2:00 pm Displayed March 5 – 9, 2013 First-in-Human Studies of Brain PDE2A (0) The histamine skin prick test: An analysis of the method for use in clinical trials. 0162819 , a Biotin 1 Carboxylase Inhibitor Representing a New Class of Antibacterial Compounds , Using In Vitro 2 Infection Models 3 4 5 Running Title : PK / PD Characterization : Novel Biotin Carboxylase Inhibitor 6 7 8 (0) More Papers This paper list is powered by the following services:
What Schools Are Affiliated With Adam Ogden? Adam Ogden is affiliated with the following schools:
